2312 Japanese phase I trial of hypoxia-activated prodrug evofosfamide (TH-302) as monotherapy in patients with solid tumors or in combination with gemcitabine in patients with advanced pancreatic cancer. (September 2015) - Mitsunaga, S.; Takahashi, H.; Doi, T.; Johne, A.; Wang, J.; Shimizu, A.; Ikeda, M.